A multicentric randomised pilot study on “low dose immunotherapy” taken up by doctors at a private cancer hospital in Bengaluru has claimed effective results on head and neck cancer patients.
“This open-labelled prospective study provides an affordable cancer treatment option in the management of head and neck cancers,” claimed doctors at the HCG Cancer hospital where the study was done.
Addressing presspersons here on Wednesday, Satheesh C.T., Consultant - Medical and Hemato Oncology - and director of Clinical Trials at the hospital said the multicentric study assesses the effectiveness of neoadjuvant therapy combining low-dose immunotherapy Nivolumab and the TPF regimen (docetaxel, cisplatin, and 5-fluorouracil) compared to neoadjuvant chemotherapy (NACT) with the TPF regimen alone.
